Europe Human Insulin Market Size, Share, and COVID-19 Impact Analysis, By Type (Analog Insulin, and Traditional Insulin), By Diabetes Type (Diabetes 1 and Diabetes 2), By Distribution Channel (Hospital Pharmacy, and Retail & Online Pharmacy), and Europe Human Insulin Market Insights, Industry Trend, Forecasts to 2035

Europe Human Insulin Market Insights Forecasts to 2035

• The Europe Human Insulin Market Size was Estimated at USD 19.27 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 1.49% from 2025 to 2035
• The Europe Human Insulin Market Size is Expected to Reach USD 22.68 Billion by 2035

According to a research report published by Spherical Insights & Consulting, the Europe Human Insulin Market Size is anticipated to reach USD 22.68 Billion by 2035, Growing at a CAGR of 1.49% from 2025 to 2035. Increased diabetes prevalence, sophisticated insulin products, enhanced diagnosis, creative delivery devices, robust government reimbursement, and increased demand for individualized treatment all propel higher insulin adoption, which improves patient outcomes and propels steady growth within the European human insulin market.

Market Overview

The Europe human insulin market entails the manufacture, supply, and sale of insulin products for the control of diabetes in European nations. Insulin is a critical hormone that controls blood glucose levels and is needed by patients with Type 1 diabetes and most patients with late-stage Type 2 diabetes. The market encompasses conventional human insulin and sophisticated analog insulin formulations, administered through different devices like syringes, pens, and insulin pumps. The ultimate goal of this market is to make available effective, safe, and affordable insulin therapies that enhance better control of blood sugar, minimize the risk of complications, and enhance diabetic patients' quality of life. It also seeks to stimulate innovation for delivery systems and formulations to address varied patient needs in various healthcare settings. Additionally, advances like ultra-long-acting insulins, once-weekly dosing, smart pens, and combined insulin pump technologies are transforming diabetes management in Europe. Expanded e-commerce, cold chain logistics improvement, and digitalization of health are improving insulin supply and patient compliance. Overall, the Europe human insulin market is experiencing steady growth, supported by technological advancement, policy support, and rising healthcare demand for better diabetes management.

Report Coverage

This research report categorizes the market for Europe human insulin market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe human insulin market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe human insulin market.

Driving Factors

Europe is witnessing a consistent rise in Type 2 diabetes cases along with an aging population, obesity, and a lifestyle of physical inactivity. This increasing base of patients directly supports the insulin therapy demand, propelling the market growth in the region. Furthermore, advances like long-acting analog insulins and ultra-long-acting ones enhance glucose control and decrease the side effects of hypoglycemia. These advances render insulin therapy safer and more convenient, leading to increased adoption and market growth.

Restraining Factors

Analog insulins, popular in Europe, are generally costly. They may restrict patient access, particularly in the case of less extensive healthcare in countries or the absence of insurance coverage, curbing market development and affordability. In addition, Europe has strict regulatory conditions for the approval, production, and distribution of insulin. These are time-consuming and costly procedures that prolong time and expense for firms to introduce new products, decelerating innovation and market entry for new competitors.

Market Segmentation

The Europe human insulin market share is classified into type, diabetes type, and distribution channel.

• The analog insulin segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

The Europe human insulin market is segmented by type into analog insulin and traditional insulin. Among these, the analog insulin segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The growth is attributed to analog insulins offering more consistent absorption and action profiles than conventional insulin. This results in improved control of blood sugar, lowering both the risk of hyperglycemia and hypoglycemia, hence analog insulin is the desired option for both patients and clinicians.

• The diabetes 2 segment accounted for the highest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

The Europe human insulin market is segmented by diabetes type into diabetes 1 and diabetes 2. Among these, the diabetes 2 segment accounted for the highest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth is due to type 2 diabetes strikes the majority of diabetic patients within Europe with a prevalence of around 90-95%. This sizable patient pool logically necessitates greater demand for insulin therapy since many patients need to use insulin to control their condition effectively in a long-term context.

• The hospital pharmacy segment accounted for a significant share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period.

The Europe human insulin market is segmented by distribution channel into hospital pharmacy and retail & online pharmacy. Among these, the hospital pharmacy segment accounted for a significant share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. The growth is driven by insulin a prescription drug requiring medical supervision. Hospitals are initial sites where physicians prescribe and modify insulin doses, hence the ideal route for delivery of insulin in controlled clinical supervision is through hospital pharmacies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved in the Europe human insulin market. It also includes a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novo Nordisk A/S
• MannKind Corporation
• Pfizer
• Wockhardt
• Biocon
• Lupin
• Tonghua Dongbao Pharmaceutical Co.
• Eli Lilly and Company
• Others

Recent Developments:

• In August 2024, Sanofi announced plans to invest €1.3 billion in a state-of-the-art insulin production facility in Frankfurt, Germany. This facility, spanning 36,000 square meters, aims to replace existing production plants and meet the growing global demand for insulin. Expected to commence operations by 2029, it will produce Sanofi’s Lantus insulin, a long-acting insulin used to control high blood sugar in adults and children with diabetes mellitus.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Europe, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Europe human insulin market based on the below-mentioned segments:

Europe Human Insulin Market, By Type

• Analog Insulin
• Traditional Insulin

Europe Human Insulin Market, By Diabetes Type

• Diabetes 1
• Diabetes 2

Europe Human Insulin Market, By Distribution Channel

• Hospital Pharmacy
• Retail & Online Pharmacy